Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
- Baseline Demographics
- COMP005 Efficacy: A Closer Look
- COMP006 Efficacy: A Closer Look
- Safety Profile: A Closer Look
- Commercial Update
- Q&A
On a webcast, Compass Pathways management shared further insight into this morning’s Phase 3 program readout, which featured a first look at topline data from COMP006 and 26-week data from COMP005.
We covered that topline in depth, via in-house analysis and discussion with CEO Kabir Nath and CMO Guy Goodwin: Breaking: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Invites Debate. Since market open, shares in Compass have risen sharply, up over 30% at the time of writing.
Here, we share the slides from the webcast and commentary for those of you who want to dive even deeper...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks